Publications by authors named "Roxana Azimi"

6Publications

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

J Clin Oncol 2018 07 10;36(19):1905-1912. Epub 2018 May 10.

Giulia C. Leonardi, Sasha Kravets, Suzanne E. Dahlberg, and Mark M. Awad, Dana-Farber Cancer Institute; Justin F. Gainor and Roxana Azimi, Massachusetts General Hospital; Lydia Gedmintas, Brigham and Women's Hospital, Boston, MA; Mehmet Altan, MD Anderson Cancer Center, Houston, TX; Hira Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Matthew D. Hellmann, Weill Cornell Medical College, and Parker Institute for Cancer Immunotherapy, New York, NY; and Jonathan W. Riess, University of California Davis Comprehensive Cancer Center, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.0305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553840PMC
July 2018